Alster Stem Cells - Intramyocardial Stem Therapy
Not Applicable
Terminated
- Conditions
- Acute Myocardial InfarctionEarly Left Ventricular Dysfunction
- Registration Number
- NCT00939042
- Lead Sponsor
- Asklepios proresearch
- Brief Summary
Study to assess the efficacy of intramyocardial bone marrow derived mononuclear cell therapy concerning left ventricular ejection fraction as measured by echocardiography.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- LVDF < 45% after timely (max. 6 hours after the onset of symptomps) successful PCI
- conventional therapy according to the ESC guidelines for heart failure
- BMI > 20 and < 35
Exclusion Criteria
- PCI elder then 21 days
- relevant valvular disease
- history of stroke/multivessel disease/thromboembolic event etc.
- DM Type I
- pregancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Assessment of the effect of a direct intramyocardial injection of bone marrow mononuclear cells (BMNC) on heart function (LVEF). 12 months
- Secondary Outcome Measures
Name Time Method Comparison of th eexplanatory power of echocardiography, endocardial left ventricular electromechanical mapping (LVEMM) with NOGA and cardiac MRI as an endpoint for myocardial regeneration. 12 months Collection of first evidence on the best type and time points for the determination of myocardial regeneration by NOGA and other parameters. 12 months
Trial Locations
- Locations (1)
Asklepios Klinik St. Georg
🇩🇪Hamburg, Germany
Asklepios Klinik St. Georg🇩🇪Hamburg, Germany